Sotrovimab therapy in solid organ transplant recipients with mild to moderate COVID-19: a systematic review and meta-analysis

References

• Farmani AR, Mahdavinezhad F, Moslemi R, et al. Anti-IgE monoclonal antibodies as potential treatment in COVID-19. Immunopharmacol Immunotoxicol. 2021;43(3):259–264.
   PubMed Web of Science ®Google Scholar
• Gold MS, Sehayek D, Gabrielli S, et al. COVID-19 and comorbidities: a systematic review and meta-analysis. Postgrad Med. 2020;132(8):749–755.
   PubMed Web of Science ®Google Scholar
• Grasselli G, Greco M, Zanella A, COVID-19 Lombardy ICU Network, et al. Risk factors associated with mortality among patients with COVID-19 in intensive care units in lombardy, Italy. JAMA Intern Med. 2020;180(10):1345–1355.
   PubMed Web of Science ®Google Scholar
• Okumura K, Nishida S, Dhand A. Trends in COVID-19 mortality among solid organ transplant recipients: implications for prevention. Transplantation. 2022;106(8):e380–e381.
   PubMed Web of Science ®Google Scholar
• Pereira MR, Mohan S, Cohen DJ, et al. COVID‐19 in solid organ transplant recipients: initial report from the US epicenter. Am J Transplant. 2020;20(7):1800–1808.
   PubMed Web of Science ®Google Scholar
• Kates OS, Haydel BM, Florman SS, UW COVID-19 SOT Study Team, et al. Coronavirus disease 2019 in solid organ transplant: a multicenter cohort study. Clin Infect Dis. 2021;73(11):e4090–e4099.
   PubMed Web of Science ®Google Scholar
• Saharia KK, Anjan S, Streit J, EIN COVID-19 Study Team, et al. Clinical characteristics of COVID‐19 in solid organ transplant recipients following COVID‐19 vaccination: a multicenter case series. Transpl Infect Dis. 2022;24(2):e13774.
   PubMed Web of Science ®Google Scholar
• Sun J, Zheng Q, Madhira V, National COVID Cohort Collaborative (N3C) Consortium, et al. Association between immune dysfunction and COVID-19 breakthrough infection after SARS-CoV-2 vaccination in the US. JAMA Intern Med. 2022;182(2):153–162.
   PubMed Web of Science ®Google Scholar
• Ducloux D, Bamoulid J, Chabannes M, et al. Current vaccine strategies against SARS_CoV-2 only poorly protect kidney transplant recipients. Journal of Infection. 2022;84(3):e34–e35.
   PubMed Web of Science ®Google Scholar
• Heo Y-A. Sotrovimab: first approval. Drugs. 2022;82(4):477–484.
   PubMed Web of Science ®Google Scholar
• NIH. Therapeutic management of nonhospitalized adults with COVID-19. 2022.
   Google Scholar
• Cathcart AL, Havenar-Daughton C, Lempp FA, et al. The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2. biorxiv. 2022.
   Google Scholar
• Gupta A, Gonzalez-Rojas Y, Juarez E, COMET-ICE Investigators, et al. Effect of sotrovimab on hospitalization or death among high-risk patients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2022;327(13):1236–1246.
   PubMed Web of Science ®Google Scholar
• Gupta A, Gonzalez-Rojas Y, Juarez E, COMET-ICE Investigators, et al. Early treatment for covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N Engl J Med. 2021;385(21):1941–1950.
   PubMed Web of Science ®Google Scholar
• Yamasoba D, Kosugi Y, Kimura I, et al. Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies. Lancet Infect Dis. 2022;22(7):942–943.
   PubMed Web of Science ®Google Scholar
• Sanders J-SF, Bemelman FJ, Messchendorp AL, RECOVAC Collaborators, et al. The RECOVAC immune-response study: the immunogenicity, tolerability, and safety of COVID-19 vaccination in patients with chronic kidney disease, on dialysis, or living with a kidney transplant. Transplantation. 2022;106(4):821–834.
   PubMed Web of Science ®Google Scholar
• Gliga S, Luebke N, Killer A, et al. Longitudinal analysis of escape mutations in SARS-CoV-2 omicron variants after sotrovimab use in immunodeficient patients. 2022.
   Google Scholar
• Piccicacco N, Zeitler K, Montero J, et al. Real-world effectiveness of early remdesivir and sotrovimab in the highest-risk COVID-19 outpatients during the omicron surge. J Antimicrob Chemother. 2022;77(10):2693–2700.
   PubMed Web of Science ®Google Scholar
• Solera JT, Árbol BG, Alshahrani A, et al. Impact of vaccination and early monoclonal antibody therapy on COVID-19 outcomes in organ transplant recipients during the omicron wave. Clin Infect Dis. 2022;75(12):2193–2200.
   PubMedGoogle Scholar
• Wong G, Rowlandson M, Sabanayagam D, et al. COVID-19 infection with the omicron SARS-CoV-2 variant in a cohort of kidney and kidney pancreas transplant recipients: clinical features, risk factors, and outcomes. Transplantation. 106(9):1860–1866.
   PubMed Web of Science ®Google Scholar
• Dhand A, Lobo SA, Wolfe K, et al. Casirivimab-imdevimab for treatment of COVID-19 in solid organ transplant recipients: an early experience. Transplantation. 2021;105(7):e68–e69.
   PubMedGoogle Scholar
• Fernandes G, Devresse A, Scohy A, et al. Monoclonal antibody therapy for SARS-CoV-2 infection in kidney transplant recipients: a case series from Belgium. Transplantation. 2022;106(1):e107–e108.
   PubMed Web of Science ®Google Scholar
• Yetmar ZA, Beam E, O’Horo JC, et al. editors. Monoclonal antibody therapy for COVID-19 in solid organ transplant recipients. Open Forum Infect Dis. 2021;24(1):e13759.
   Google Scholar
• Villanego F, Mazuecos A, Cubillo B, et al. Treatment with sotrovimab for SARS-CoV-2 infection in a cohort of high-risk kidney transplant recipients. Clin Kidney J. 2022;15(10):1847–1855.
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1–e34.
   PubMed Web of Science ®Google Scholar
• Chavarot N, Melenotte C, Amrouche L, et al. Early treatment with sotrovimab monoclonal antibody in kidney transplant recipients with omicron infection. Kidney International. 2022;101(6):1290–1293.
   PubMed Web of Science ®Google Scholar
• Gleeson S, Martin P, Thomson T, et al. Kidney transplant recipients and omicron: outcomes, effect of vaccines and the efficacy and safety of novel treatments. medRxiv. 2022.
   Google Scholar
• Hedvat J, Lange NW, Salerno DM, et al. COVID‐19 therapeutics and outcomes among solid organ transplant recipients during the omicron BA. 1 era. Am J Transplant. 2022;22(11):2682–2688.
   PubMed Web of Science ®Google Scholar
• Radcliffe C, Palacios CF, Azar MM, et al. Real‐world experience with available, outpatient COVID‐19 therapies in solid organ transplant recipients during the omicron surge. Am J Transplant. 2022;22(10):2458–2463.
   PubMed Web of Science ®Google Scholar
• Yetmar ZA, Beam E, O'Horo JC, et al. Outcomes of bebtelovimab and sotrovimab treatment of solid organ transplant recipients with mild‐to‐moderate COVID‐19 during the omicron epoch. Transplant Infect Dis. 2022;24(4):e13901.
   Web of Science ®Google Scholar
• Cochran W, Langlee J, Barker L, et al. Short-term outcomes in a nurse coordinator–led and nurse practitioner–led sotrovimab initiative for solid organ transplant recipients during the omicron surge. Transplantation. 106(9):e424–e425.
   PubMed Web of Science ®Google Scholar
• Pinchera B, Buonomo AR, Scotto R, Federico II COVID team, et al. Sotrovimab in solid organ transplant patients with early, mild/moderate SARS-CoV-2 infection: a single-center experience. Transplantation. 2022;106(7):e343–e345.
   PubMed Web of Science ®Google Scholar
• Dhand A, Okumura K, Wolfe K, et al. Sotrovimab for treatment of COVID-19 in solid organ transplant recipients. Transplantation. 2022;106(7):e336–e337.
   PubMed Web of Science ®Google Scholar
• Degli Antoni M, Giagulli C, Messali S, et al. Potential benefit of early treatment with sotrovimab in patients with high risk for severe COVID-19 carrying BA. 2 Infection. Preprints 2022.
   Google Scholar
• Malahe SRK, Hoek RA, Dalm VA, et al. Clinical characteristics and outcome of immunocompromised patients with COVID-19 caused by the omicron variant: a prospective observational study. medRxiv. 2022.
   Google Scholar
• Fernandes G, Devresse A, Scohy A, et al. Monoclonal antibody therapy in kidney transplant recipients with Delta and omicron variants of SARS-CoV-2: a single-center case series. Kidney Med. 2022;4(6):100470.
   PubMedGoogle Scholar
• Dhand A, Razonable RR. COVID-19 and solid organ transplantation: role of anti-SARS-CoV-2 monoclonal antibodies. Curr Transpl Rep. 2022;9(1):26–34.
   PubMedGoogle Scholar
• Teo SP, Department of Internal Medicine, RIPAS Hospital, Bandar Seri Begawan, BA 1710, Brunei Darussalam. Sotrovimab for treatment of COVID-19 infections. APT. 2022;4(2):56–59.
   Google Scholar
• Yetmar ZA, Bhaimia E, Razonable RR. Antispike monoclonal antibodies for prevention and treatment of coronavirus disease-2019 in solid organ transplant recipients. Curr Opin Organ Transplant. 2022;27(4):269–276.
   PubMed Web of Science ®Google Scholar
• Yang M, Li A, Wang Y, et al. Monoclonal antibody therapy improves severity and mortality of COVID-19 in organ transplant recipients: a meta-analysis. J Infect. 2022;85(4):436–480.
   Web of Science ®Google Scholar
• Kreuzberger N, Hirsch C, Chai KL, Cochrane Haematology Group, et al. SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19. Cochr Database Systematic Rev. 2021;2021(9):CD013825.
   Google Scholar
• Hoffmann M, Krüger N, Schulz S, et al. The omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic. Cell. 2022;185(3):447–456. e11.
   PubMed Web of Science ®Google Scholar
• Iketani S, Liu L, Guo Y, et al. Antibody evasion properties of SARS-CoV-2 omicron sublineages. Nature. 2022;604(7906):553–556.
   PubMed Web of Science ®Google Scholar
• Takashita E, Kinoshita N, Yamayoshi S, et al. Efficacy of antiviral agents against the SARS-CoV-2 omicron subvariant BA. 2. N Engl J Med. 2022;386(15):1475–1477.
   PubMed Web of Science ®Google Scholar
• Jensen B, Luebke N, Feldt T, et al. Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in Germany. Lancet Reg Health Eur. 2021;8:100164.
   PubMedGoogle Scholar
• Destras G, Bal A, Simon B, et al. Sotrovimab drives SARS-CoV-2 omicron variant evolution in immunocompromised patients. medRxiv. 2022.
   Google Scholar
• Vellas C, Tremeaux P, Del Bello A, et al. Resistance mutations in SARS-CoV-2 omicron variant in patients treated with sotrovimab. Clin Microbiol Infect. 2022;28(9):1297–1299.
   PubMed Web of Science ®Google Scholar